[1]
|
W. G. Land, “Innate Immunity-Mediated Allograft Rejection and Strategies to Prevent It,” Transplantation Proceedings, Vol. 39, No. 3, 2007, pp. 667-672.
doi:10.1016/j.transproceed.2007.01.052
|
[2]
|
J. Gurevitch, I. Frolkis and Y. Yuhas, “Tumor Necrosis-Alpha Is Released from the Isolated Heart Undergoing Ischemia and Reperfusion,” The American College of Cardiology, Vol. 28, No. 1, 1966, pp. 247-252.
doi:10.1016/0735-1097(96)00105-2
|
[3]
|
D. M. Yellon and D. J. Hausenloy, “Mechanisms of Disease: Myocardial Reperfusion Injury,” The New England Journal of Medicine, Vol. 357, No. 9, 2007, pp. 1121-1135. doi:10.1056/NEJMra071667
|
[4]
|
W. G. Land, “The Role of Postischemic Reperfusion Injury and Other Nonantigen-Dependent Inflammatory Pathways in Transplantation,” Transplantation, Vol. 79, No. 5, 2005, pp. 505-514.
doi:10.1097/01.TP.0000153160.82975.86
|
[5]
|
J. M. Downey, “Free Radicals and Their Involvement during Long-Term Myocardial Ischemia and Reperfusion,” Annual Review Physiology, Vol. 52, 1990, pp. 487-504.
|
[6]
|
E. Noiri, A. Nakao, K. Uchida, et al., “Oxidative and Nitrosative Stress in Acute Renal Ischemia,” American Journal of Physiological Renal Physiology, Vol. 281, No. 5, 2001, pp. F948-F957.
|
[7]
|
J. T. Flaherty, B. Pitt, J. W. Gruber, et al., “Recombinant Human Superoxide Dismutase (h-SOD) Fails to Improve Recovery of Ventricular Function in Patients Undergoing Coronary Angioplasty for Acute Myocardial Infarction,” Circulation, Vol. 89, No. 5, 1994, pp. 1982-1991.
doi:10.1161/01.CIR.89.5.1982
|
[8]
|
W. G. Land, “Emerging role of Innate Immunity in Organ Transplantation Part II: Potential of Damage-Associated Molecular Patterns to Generate Immunostimulatory Dendritic Cells,” Transplantation Reviews, Vol. 26, No. 2, 2012, pp. 73-87. doi:10.1016/j.trre.2011.02.003
|
[9]
|
G. Liu, H. Ma, L. Jiang and Y. Zhao, “Allograft Inflammatory Factor-1 and Its Immune Regulation,” Autoimmunity, Vol. 40, No. 2, 2007, pp. 95-102.
doi:10.1080/08916930601083946
|
[10]
|
F. Del Galdo and S. A. Jimenez, “T Cell Expressing Allograft Inflammatory Factor-1 Display Increases Chemotaxis and Induce a Pro-Fibrotic Phenotype in Normal Fibroblasts in vitro,” Arthritis Rheumatism, Vol. 56, No. 10, 2007, pp. 3478-3488. doi:10.1002/art.22877
|
[11]
|
U. Utans, R. J. Arceci, Y. Yamashita and M. E. Russell, “Cloning and Characterization of Allograft Inflammatory Factor-1: A Novel Macrophage Factor Identified in Rat Cardiac Allografts with Chronic Rejection,” Journal of Clinical Investigation, Vol. 95, No. 5, 1995, pp. 2954-2962. doi:10.1172/JCI118003
|
[12]
|
U. Utans, W. C. Quist, B. M. McManus, J. E. Wilson and R. J. Arceci, “Allograft Inflammatory Factor-1. A Cytokine Responsive Macrophage Molecule Expressed in Transplanted Human Hearts,” Transplantation, Vol. 61, No. 9, 1996, pp. 1387-1392.
doi:10.1097/00007890-199605150-00018
|
[13]
|
S. E. Kelemen and M. V. Autieri, “Expression of Allograft Inflammatory Factor-1 in T Lymphocytes: A Role in T-Lymphocyte Activation and Proliferative Arteriopathies,” American Journal of Pathology, Vol. 167, No. 2, 2005, pp. 619-626. doi:10.1016/S0002-9440(10)63003-9
|
[14]
|
M. V. Autieri, C. Carbone and A. Mu, “Expression of Allograft Inflammatory Factor-1 Is a Marker of Activation Human Vascular Smooth Muscle Cells and Arterial Injury,” Arteriosclerosis Thrombosis Vascular Biology, Vol. 20, No. 7, 2000, pp. 1737-1744.
doi:10.1161/01.ATV.20.7.1737
|
[15]
|
M. H. Deininger, K. Seid, S. Engel, R. Meyermann and H. J. Schluesener, “Allograft Inflammatory Factor-1 Defines a Distinct Subset of Infiltrating Macrophages/microglial cells in Rat and Human Gliomas,” Acta Neurophathology, Vol. 100, No. 6, 2000, pp. 673-680.
doi:10.1007/s004010000233
|
[16]
|
Y. Tian, S. Jain, S. E. Kelemen and M. V. Autieri, “AIF-1 Expression Regulates Endothelial Cell Activation, Signal Transduction, and Vasculogenesis,” American Journal of Physiology Cell Physiology, Vol. 296, No. 2, 2009, pp. C256-C266. doi:10.1152/ajpcell.00325.2008
|
[17]
|
R. Kuschel, M. H. Deininger, R. Meyermann, A. Bornemann, Z. Yablonka-Reuveni and H. J. Schluesener, “Allograft Inflammatory Factor-1 Is Expressed by Macrophages in Injured Skeletal Muscle and Abrogates Proliferation and Differentiation of Satellite Cells,” Journal of Neurophatology Experimental Neurology, Vol. 59, No. 4, 2000, pp. 323-332.
|
[18]
|
C. Orsmark, T. Skoog, L. Jeskanen, J. Kere and U. Saarialho-Kere, “Expression of Allograft Inflammatory Factor-1 in Inflammatory Skin Disorders,” Acta Dermato-Venereologica, Vol. 87, No. 3, 2007, pp. 223-227.
|
[19]
|
T. C. Lund, L. B. Anderson, V. McCullar, et al., “iTRAQ Is a Useful Method to Screen for Membrane-Bound Proteins Differentially Expressed in Human Natural Killer Cell Types,” Journal of Proteome Research, Vol. 6, No. 2, 2007, pp. 644-653. doi:10.1021/pr0603912
|
[20]
|
Y. Tsubata, M. Sakatsume, A. Ogawa, et al., “Expression of Allograft Inflammatory Factor-1 in Kidneys: A Novel Molecular Component of Podocyte,” Kidney International, Vol. 70, No. 11, 2006, pp. 1948-1954.
|
[21]
|
C. Kohler, “Allograft Inflammatory Factor-1/Ionized Calcium-binding Adapter Molecule 1 Is Specifically Expressed by most Subpopulations of Macrophages and Spermatids in Testis,” Cell and Tissue Research, Vol. 330, No. 2, 2007, pp. 291-302.
doi:10.1007/s00441-007-0474-7
|
[22]
|
D. O. Taylor, L. B. Edwards, M. M. Boucek, et al., “Registry of the International Society for Heart and Lung Transplantation: Twenty-second Official Adult Heart Transplant Report, 2005,” Journal of Heart Lung Transplantation, Vol. 24, No. 8, 2005, pp. 945-955.
doi:10.1016/j.healun.2005.05.018
|
[23]
|
X. Zhou, Z. He, J. Henegar, B. Allen and S. Bigler, “Expression of Allograft Inflammatory Factor-1 (AIF-1) in Acute Cellular Rejection of Cardiac Allografts,” Cardiovascular Pathology, Vol. 20, No. 5, 2011, pp. e177-e184.
doi:10.1016/j.carpath.2010.08.002
|
[24]
|
A. K. Barker, D. O. McDaniel, X. Zhou, et al., “Combined Analysis of Allograft Inflammatory Factor-1, Interleukin-18, and Toll-Like Receptor Expression and Association with Allograft Rejection and Coronary Vasculopathy,” The American Surgeon, Vol. 76, No. 8, 2010, pp. 872-878.
|
[25]
|
A. M. Sheridan and J. V. Bonventre, “Cell Biology and Molecular Mechanisms of Injury in Ischemic Acute Renal Failure,” Current Opinion Nephrology Hypertension, Vol. 9, No. 4, 2000, pp. 427-434.
doi:10.1097/00041552-200007000-00015
|
[26]
|
D. J. Kaczorowski, A. Tsung and T. R. Billiar, “Innate Immune Mechanisms in Ischemia/Reperfusion,” Frontiers Bioscience, Vol. 1, No. 6, 2009, pp. 91-98.
|
[27]
|
M. Takahashi, “Role of the Inflammasome in Myocardial Infarction,” Trends in Cardiovascular Medicine, Vol. 21, No. 2, 2011, pp. 37-41. doi:10.1016/j.tcm.2012.02.002
|
[28]
|
M. V. Autieri, S. Kelemen, B. A. Thomas, E. D. Feller, B. I. Goldman and H. J. Eisen, “Allograft Inflammatory Factor-1 Expression Correlates with Cardiac Rejection and Development of Cardiac Allograft Vasculopathy,” Circulation, Vol. 106, No. 17, 2002, pp. 2218-2223.
doi:10.1161/01.CIR.0000035652.71915.00
|
[29]
|
D. O. McDaniel, X. Zhou, C. K. Moore and G. Aru, “Cardiac Allograft Rejection Correlates with Increased Expressions of Toll-like Receptor 2 and 4 and Allograft Inflammatory Factor 1,” Transplantation Proceedings, Vol. 42, No. 10, 2010, pp.5235-4237.
doi:10.1016/j.transproceed.2010.09.091
|
[30]
|
Z. F. Yang, D. W. Ho, C. K. Lau, et al., “Allograft Inflammatory Factor-1 (AIF-1) Is Crucial for the Survival and Pro-Inflammatory Activity of Macrophages,” International Immunology, Vol. 17, No. 11, 2005, pp. 1391- 1397. doi:10.1093/intimm/dxh316
|
[31]
|
Y. Tian, S. E. Kelemen and M. V. Autieri, “Inhibition of AIF-1 Expression by Constitutive siRNA Expression Reduces Macrophage Migration, Proliferation, and Signal Transduction Initiated by Atherogenic Stimuli,” American Journal of Physiology Cell Physiology, Vol. 290, No. 4, 2006, pp. C1083-C1091. doi:10.1152/ajpcell.00381.2005
|
[32]
|
Y. Nagakawa, S. Nomoto, Y. Kato, et al., “Over-Expression of AIF-1 in Liver Allograft and Peripheral Blood Correlates with Acute Rejection after Transplantation in Rats,” American Journal of Transplantation, Vol. 4, No. 12, 2004, pp. 1949-1957.
doi:10.1111/j.1600-6143.2004.00621.x
|
[33]
|
W. Jiang, L. Kong, X. Wu and X. Wang, “Allograft Inflammatory Factor-1 Is Up-Regulated in Warm and Cold Ischemia-Reperfusion Injury in Rat Liver and May Be Inhibited by FK506,” Journal of Surgical Research, Vol. 165, No. 1, 2011, pp. 158-164.
doi:10.1016/j.jss.2009.05.038
|
[34]
|
E. Antiga, W. Volpi, D. Torchia, P. Fabbri and M. Caproni, “Effects of Tacrolimus Ointment on Toll-Like Receptors in Atopic Dermatitis,” Clinical Experimental Dermatology, Vol. 36, No. 3, 2011, pp. 235-241.
doi:10.1111/j.1365-2230.2010.03948.x
|
[35]
|
A. Gluba, M. Banach, S. Hannam, D. P. Mikhailidis, A. Sakowicz and J. Rysz, “The Role of Toll-Like Receptor in Renal Diseases,” Nature Review Nephrology, Vol. 6, No. 4, 2010, pp. 224-235. doi:10.1038/nrneph.2010.16
|
[36]
|
D. R. Goldstein, “Toll Like Receptors and Acute Allograft Rejection,” Transplant Immunology, Vol. 17, No. 1, 2006, pp. 11-15. doi:10.1016/j.trim.2006.09.012
|
[37]
|
C. A. Farrar, B. Keogh, W. McCormack, et al., “Inhibition of TLR2 Promotes Graft Function in a Murine Model of Renal Transplant Ischemia-Reperfusion Injury,” Federation American Society Experimental Biology Journal, Vol. 26, No. 2, 2012, pp. 799-807.
|
[38]
|
F. Arslan, M. B. Smeets, A. A. O’Neill, et al., “Myocardial Ischemia/Reperfusion Injury Is Mediated by Leukocytic Toll-like Receptor-2 and Reduced by Systemic Administration of a Novel Anti-Toll-like Receptor-2 Antibody,” Circulation, Vol. 121,No. 1, 2010, pp. 80-90.
doi:10.1161/CIRCULATIONAHA.109.880187
|
[39]
|
S. Frantz, L. Kobzik, K. Young-Dae, et al., “Toll4 (TLR4) Expression in Cardiac Myocytes in Normal and Failing Myocardium,” Journal of Clinical Investigation, Vol. 104, No. 3, 1999, pp. 271-280. doi:10.1172/JCI6709
|